Key result
In patients with left ventricular thrombus, DOAC use was associated with a significantly lower 1-year incidence of any stroke or systemic embolism compared to warfarin (6% vs 26.6%, p=0.0001).
Why the study?
Societal guidelines recommend warfarin for left ventricular thrombus, reserving DOACs only for intolerant patients, prompting evaluation of the natural history of LVT comparing warfarin and DOAC use.
Do direct oral anticoagulants (DOACs) prevent stroke and promote thrombus resolution as effectively as warfarin in patients with left ventricular thrombus?
Observational (n=110)
No
Do direct oral anticoagulants (DOACs) prevent stroke and promote thrombus resolution as effectively as warfarin in patients with left ventricular thrombus?
Absolute Event Rate: 6% vs 26.6%
p-value: p=0.0001
In patients with left ventricular thrombus, DOACs demonstrated similar rates of stroke prevention and thrombus resolution compared to warfarin, challenging current guidelines that reserve DOACs only for those unable to tolerate warfarin.
No takes yet. Share an insight, caveat, or question.
DOACs may be considered in warfarin-intolerant LVT patients; leaves open comparative efficacy and safety versus warfarin in RCTs.
Ali et al. (2020) conducted an observational in Left ventricular thrombus (n=110). Direct oral anticoagulants (DOACs) vs. Warfarin was evaluated on Any stroke or systemic embolism at 1 year (p=0.0001). In patients with left ventricular thrombus, DOAC use was associated with a significantly lower 1-year incidence of any stroke or systemic embolism compared to warfarin (6% vs 26.6%, p=0.0001).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: